Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies

Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies

PURPOSEMounting data suggest that lower doses of anti-PD(L)1 agents can be as efficacious as label-approved doses at a fraction of its cost. We compare the outcomes of patients treated with low-dose (LD) and with conventional-dose (CD) anti-PD(L)1 agents.METHODSThis observational study evaluates the...

Full description

Saved in:
Bibliographic Details
Main Authors: Iza Andrade de A. Souza, Beatriz de M. Dobbert, Barbara G. Sao Jose, Joao Pedro Homse-Netto, Larissa L. Furlan, Maira S. Abreu, Camila Ferrari, Bruno Uchoa, Kathia Abdallah, Stephano N. Lucio, Joao A. Soler, Fabio L.C. Fernandez, Luiza Ferreira, Joao D. Guedes, Aline F. Fares, Daniel V. Araujo
Format: Article
Language:English
Published: American Society of Clinical Oncology 2024-11-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.24.00122
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ascopubs.org/doi/10.1200/GO.24.00122

Similar Items